Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol‐fed rats
The DOI matches its Crossref record.
Abstract
Male adult Wistar rats received daily (at 9 a.m. and 5 p.m.) 10 μg of zinc‐protamine glucagon by subcutaneous injection for 8 days. Plasma cholesterol levels were decreased by 36% in fed rats, 33% in cholesterol‐fed rats and by 55% in fasted rats. Lipoproteins were separated into 22 fractions by ultracentrifugation using a density gradient. Glucagon administration decreased the cholesterol content in all lipoproteins except low density lipoprotein (LDL 1) (1.006–1.040) and very low density lipoprotein (VLDL) from cholesterol‐fed rats. The main decrease (−57 to −81%) was observed in 1.050–1.100 g/mL lipoproteins (LDL 2 and HDL 2), which contained a large amount of apo E, while HDL 3 cholesterol was not affected. Triacylglycerol levels were decreased only in chylomicrons and VLDL (−70%) of fed and cholesterol‐fed rats, while plasma and lipoprotein triacylglycerol levels were not changed in fasted rats treated with glucagon. In normally fed rats glucagon administration increased by 42% the fractional catabolic rate of [125 I]HDL 2 while the absolute catabolic rate appeared to be unchanged. Glucagon seems to be a potent hypolipidemic agent affecting mainly the apo E‐rich lipoproteins. Its chronic administration limits lipoprotein accumulation which occurs upon cholesterol feeding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“Several studies have subsequently shown that administration of glucagon lowers circulating levels of cholesterol in humans (19, 95), rodents (231, 248, 249, 255), and dogs (476).”
BackgroundThe metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272
“Nevertheless, glucagon administration in the absence of diabetes produces potent hypolipemic actions (Bobe et al., 2003a; Eaton , 1973; Guettet et al., 1991) including decreased triglyceride (TG) and very low density lipoproteins (VLDL) release by the liver (Bobe et al., 2003a; Guettet et al.,…”
The α-cell in diabetes mellitus
Gromada, J., Chabosseau, P., & Rutter, G. A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0097-y · Cited by 143
Metadata
- Authors
- Guettet, C., Rostaqui, N., Mathe, D., Lecuyer, B., Navarro, N., & Jacotot, B.
- Venue
- Lipids
- Publisher
- Wiley
- Published
- 1991-06
- Volume
- 26
- Issue
- 6
- Pages
- 451-458
- ISSN
- 0024-4201 (ISSN-L)
- 1558-9307
- OpenAlex
- W2012462997
- Cited by
- 29
- References
- 0
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol‐fed rats. https://app.cochat.ai/papers/10.1007/bf02536072
- The paper
- Guettet, C., Rostaqui, N., Mathe, D., Lecuyer, B., Navarro, N., & Jacotot, B. (1991). Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol‐fed rats. Lipids. https://doi.org/10.1007/bf02536072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.